Condition
Purpura, Thrombotic Thrombocytopenic
Total Trials
5
Recruiting
0
Active
0
Completed
2
Success Rate
66.7%-20% vs avg
Key Insights
Highlights
Success Rate
67% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 39/100
Termination Rate
20.0%
1 terminated out of 5 trials
Success Rate
66.7%
-19.8% vs benchmark
Late-Stage Pipeline
40%
2 trials in Phase 3/4
Results Transparency
50%
1 of 2 completed with results
Key Signals
1 with results67% success
Data Visualizations
Phase Distribution
5Total
Early P 1 (1)
P 2 (2)
P 3 (1)
P 4 (1)
Trial Status
Withdrawn2
Completed2
Terminated1
Trial Success Rate
66.7%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT02854059Phase 2TerminatedPrimary
IdeS in Asymptomatic Antibody-Mediated Thrombotic Thrombocytopenic Purpura (TTP) Patients
NCT01808521Early Phase 1CompletedPrimary
A Pilot Study of N-acetylcysteine in Thrombotic Thrombocytopenia Purpura
NCT01433003Phase 3WithdrawnPrimary
The Plasma Large-Volume Exchange RCT
NCT01754545Phase 4WithdrawnPrimary
Prophylactic Plasma Infusion Therapy for Congenital Thrombotic Thrombocytopenic Purpura
NCT00632242Phase 2CompletedPrimary
ARC1779 Injection in Patients With Von Willebrand Factor-Related Platelet Function Disorders
Showing all 5 trials